Evidently, these results demonstrated the potential of the technique for improved diagnosis when compared to the most commonly used serum biomarker for ovarian cancer, cancer antigen 125 (CA-125), which has been found to be unacceptable for early-stage detection due to its low sensitivity of 50–60% and it is only elevated in approximately 60% of patients [50,51]. The gene discussed is MUC16; the disease is ovarian carcinoma.